newdrugapprovals.org
CFG 920, Novartis Scientists team up with Researchers at Aurigene, Bangalore, India,
CFG920, Inhibitor Of Prostate Cancer With Fewer Cardiac Side Effects Cas 1260006-20-9 Novartis Target: CYP17/CYP11B2 Disease: Castration-resistant prostate cancer MF C14H13ClN4O MW: 288.0778 Elemen…